Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer.

Trial Profile

Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 Jul 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 09 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top